Clinical Trials Logo

Squamous Cell Carcinoma in Situ clinical trials

View clinical trials related to Squamous Cell Carcinoma in Situ.

Filter by:
  • None
  • Page 1

NCT ID: NCT05381597 Recruiting - Clinical trials for Superficial Basal Cell Carcinoma

5-Fluorouracil and Calcipotriene for Treatment of Low Grade Skin Cancer

Start date: October 15, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

The investigators will compare the application of two different creams for the treatment of low-risk skin cancers-superficial basal cell carcinoma (sBCC) and squamous cell carcinoma in situ (SCCis). 5-Fluorouracil cream is currently FDA approved for the treatment of superficial basal cell carcinoma and is routinely used by dermatologists across the country and at Boston Medical Center (BMC) for SCCis. The normal treatment regimen is 4 weeks of the 5-fluorouracil cream for both skin cancers. The application of a compounded cream consisting of 1:1 ratio 5-fluorouracil with calcipotriene will be tested. This combination cream has been shown to clear pre-skin cancers called actinic keratoses and prevent future skin cancers from developing. This combination cream for 7-14 days to see if this shorter treatment course provides clearance of the 2 types of skin cancer. This combination cream is successfully used in this manner to treat other subtypes of related skin cancers. This will be a pilot study with The primary endpoint for this pilot randomized single blinded clinical trial will be the response to treatment (yes versus no). The lesions will be assessed clinically for clearance of cancer, as would normally be done and is consistent with how comparable studies have assessed clearance. Participants will be followed closely afterwards for three years with visits at 6 months, which does not vary from standard practice. If the lesions are not clear of cancer or equivocal clinically, the lesions will be re-biopsied and normal standard of care procedure will take place.

NCT ID: NCT04844983 Completed - Clinical trials for Squamous Cell Carcinoma in Situ

A Study to Evaluate Safety, Efficacy of Intralesional Injection of STP705 in Patients With isSCC

Start date: May 18, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this trial is to evaluate safety, tolerability and efficacy of various doses of STP705 administered as intralesional injection in subjects with cutaneous squamous cell carcinoma (in situ) skin cancer (isSCC).

NCT ID: NCT04695015 Not yet recruiting - Melanoma (Skin) Clinical Trials

Research of Pathological Imaging Diagnosis of Ocular Tumors Based on New Artificial Intelligence Algorithm

Start date: December 31, 2020
Phase:
Study type: Observational

The purpose of this study is to establish a standardized process for obtaining digital pathological image information of ocular tumors; use modern pathological techniques to obtain the co-expression information of multiple biomarkers in the pathological tissues of ocular tumors, and finally construct standardized digital ocular tumors with biomarkers Pathology image database.

NCT ID: NCT01245972 Completed - Clinical trials for Basal Cell Carcinoma

Pilot Study of PDL to Treat BCC and SCCIS

PDLNMSC
Start date: August 2010
Phase: N/A
Study type: Interventional

This is a research study to find out more about the use of the pulsed dye laser in the treatment of basal cell carcinoma and early stage squamous cell carcinoma that has not invaded deep into the skin. The purpose of this study is to determine whether the use of the pulsed dye laser (PDL) can completely clear or regress basal cell carcinoma or early stage squamous cell carcinoma. Pulsed dye laser is a type of laser that is commonly used to treat lesions on the skin that have a prominent blood vessel component. It has been used to treat broken blood vessels on the face, hemangiomas in children and adults, leg veins, port wine stains, and other lesions with a prominent vascular component.